ClinConnect ClinConnect Logo
Search / Trial NCT06501755

Effects of Individualized Theta-tACS on a Working Memory Training at SCD

Launched by UNIVERSITY HOSPITAL TUEBINGEN · Jul 9, 2024

Trial Information

Current as of June 26, 2025

Not yet recruiting

Keywords

ClinConnect Summary

This clinical trial is exploring how a special type of brain stimulation, called individualized theta transcranial alternating current stimulation (ITF-tACS), can help improve working memory in older adults who feel like their memory is declining, a condition known as subjective cognitive decline (SCD). The study will involve participants undergoing three days of training focused on spatial working memory, which is the ability to remember and use information about where things are in space.

To be eligible for this study, participants must be at least 60 years old, have experienced memory decline for more than six months without a clear reason, and be right-handed. They should also have good eyesight and understand German well enough to give their consent and follow instructions. However, people with certain mental health conditions, significant depression or anxiety, a history of seizures, or those with specific medical devices like pacemakers will not be allowed to participate. If you join the study, you can expect to engage in memory training exercises while receiving this brain stimulation, with the goal of helping you improve your memory skills.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • age \>/= 60 years
  • subjective cognitive decline with a duration \> 6 month and without a concrete cause
  • right-handedness (score \> 48 in the Edinburgh Handedness Inventory (EHI; Oldfield, 1971))
  • corrected or sufficient eyesight
  • sufficient knowledge in German
  • ability to consent
  • Exclusion Criteria:
  • neuropsychiatric diagnose
  • score \> 13 in the DemTect (Kalbe et al., 2019)
  • score \> 4 in the Geriatric Depression Scale Short Form (GDS-SF; Sheikh \& Yesavage, 1986)
  • score \> 16 Geriatric Anxiety Scale German version(GAS-G; Gottschling et al., 2016)
  • substance abuse or dependence
  • epileptic seizure in medical history
  • metall in skalp-area
  • pacemaker
  • gravidity
  • psychiatric medication
  • benzodiazepines in a dosage \> 1 mg Lorazepam
  • participation in a tACS in history

About University Hospital Tuebingen

University Hospital Tübingen is a leading academic medical institution in Germany, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, the hospital leverages its multidisciplinary expertise and cutting-edge facilities to develop new therapeutic strategies and improve patient outcomes. With a strong focus on translational medicine, University Hospital Tübingen collaborates with various stakeholders, including pharmaceutical companies and research organizations, to facilitate the efficient and ethical conduct of trials across a wide range of medical disciplines. Their dedication to patient-centered research and rigorous scientific standards positions them at the forefront of medical advancements.

Locations

Tübingen, Baden Württemberg, Germany

Tübingen, , Germany

Patients applied

0 patients applied

Trial Officials

Prof. Dr. Christian Plewnia

Principal Investigator

Universitätsklinik für Psychiatrie und Psychotherapie Tübingen, Tübingen, DE

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported